
ABSTRACT Objective Caffeine could improve cognitive functions, but study protocols usually prohibit drinking coffee before cognitive testing. However, regular coffee consumers may experience withdrawal effects when they cannot drink their habitual coffee, which may impair cognitive performance. Therefore, we tested the effects of overnight coffee abstinence in regular coffee consumers: once allowing to drink their coffee and once not drinking coffee. The cognitive performance was compared with non‐regular coffee consumers. Methods Thirty regular coffee consumers (RCCs) and 25 non‐regular consumers (N‐RCCs) took part in this study. RCCs were tested after their habitual morning coffee (c‐RCC) and after overnight abstinence (a‐RCC); N‐RCCs were tested once. A cognitive battery assessed reaction time (RT), processing speed (digit symbol substitution test), working memory, verbal learning/memory and executive function (Stroop). Sleep quality was included as a covariate. Results Compared to c‐RCC, overnight coffee abstinence significantly slowed RTs but did not affect the performance in the other cognitive tasks. In the a‐RCC condition, but not the c‐RCC condition, the RTs were slower than those of the N‐RCCs, while accuracy measures were comparable across groups. Sleep quality did not alter these findings. Conclusions Overnight coffee abstinence selectively slowed RT, and no statistical support was found for effects on memory or executive function. This suggests that overnight coffee abstinence protocols may introduce withdrawal‐related RT slowing as a confound in habitual consumers, whereas other cognitive domains may not be affected. Allowing habitual consumers to maintain normal coffee intake could reduce this bias, supporting tailored rather than uniform abstinence requirements based on the specific outcomes studied.
ABSTRACT Objective Treatment dropout undermines psychiatric trials and clinical care, and its predictors are usually studied within one diagnosis. Using harmonized individual participant data (IPD), we investigated which dropout predictors are robust across diagnoses and which are tied to study design. Method IPD analysis of seven NIMH trials ( N = 8543). A study‐stratified Cox model (race‐complete N = 6677) tested age, sex, race, and within‐study z‐scored severity, and each predictor was graded against proportional‐hazards, equal‐coefficient (follow‐up tier), leave‐one‐study‐out, random‐effects, and severity‐recoding checks. Results Lower baseline severity robustly predicted treatment completion, significant and same‐direction under every specification: z‐score, percentile‐rank and median‐split codings (HR = 1.124, p < 0.001), leave‐one‐study‐out, random‐effects pooling, and both short and long follow‐up trials. The study‐specific severity estimates were directionally consistent in all seven trials, but the magnitude of the pooled association was driven mainly by the short‐follow‐up MDD tier (HR = 1.270, p < 0.001 vs. HR = 1.057, p = 0.026), and only STAR*D reached significance on its own. Age, sex, and race were informative but study‐dependent, varying across follow‐up horizon (equal‐coefficient test rejected for age, sex, and severity) and between studies ( I 2 = 72%–84%); proportional hazards held for age and race but not severity or sex ( χ 2 = 18.1, df = 4, p = 0.001). Conclusion Baseline symptom severity is a robust, diagnosis‐spanning marker of dropout risk and a practical target for retention support, whereas age, sex, and race need study‐specific interpretation. Grading pooled estimates with assumption checks distinguishes durable transdiagnostic signals from design‐bound ones, a template for future IPD dropout research.
ABSTRACT Objective To compare serum total tau and α‐synuclein among controls, drug‐naïve children with attention‐deficit/hyperactivity disorder (ADHD) and children with ADHD receiving methylphenidate. Methods Original ELISA spreadsheets provided 26 controls, 29 evaluable drug‐naïve participants and 32 methylphenidate‐treated participants. Boundary‐coded results (> 500 pg/mL for tau; < 938 pg/mL for α‐synuclein) were assigned the recorded boundary for rank‐based analyses. Groups were compared using Kruskal–Wallis tests and Dunn–Bonferroni contrasts; within‐group associations used Spearman correlations. Results α‐Synuclein differed among groups ( H = 49.859, p < 0.001, ε 2 = 0.570), with all pairwise contrasts significant. Tau also differed ( H = 10.492, p = 0.005, ε 2 = 0.101); drug‐naïve ADHD had lower tau than controls, whereas the treated group differed from neither comparator after correction. The α‐synuclein–tau correlation remained significant after false‐discovery‐rate adjustment only in drug‐naïve ADHD ( ρ = 0.443, adjusted p = 0.048). Conclusions Serum α‐synuclein and total tau showed distinct cross‐sectional group patterns. These associations do not establish methylphenidate effects and require prospective confirmation.
ABSTRACT Background Caffeine is consumed for its presumed cognitive benefits, yet controlled studies have repeatedly failed to find effects on inhibitory control. Cross‐sectional work suggests that people with elevated attention‐deficit/hyperactivity disorder (ADHD) symptoms may benefit from chronic, moderate caffeine consumption, but whether acute intake improves cognition in proportion to symptom severity has not been tested experimentally. Aims We tested whether 250 mg of caffeine improves active inhibition (withholding a prepared response) and reactive inhibition (resolving response conflict), and whether ADHD symptom severity moderates these effects. Methods In a preregistered, randomised, double‐blind, placebo‐controlled crossover trial, a nonclinical sample of 36 young adults received 250 mg of caffeine or placebo in counterbalanced order, with testing 45 min after ingestion. Active inhibition was assessed with a Go/No‐Go task (204 trials), reactive inhibition with an arrow flanker task (200 trials) and symptoms with the Adult ADHD Self‐Report Scale. Mixed‐effects models included treatment, symptom severity, their interaction and ten covariates; Bayes factors quantified evidence for the null. Results Both tasks produced their benchmark effects (dz = 1.24 and 1.09) and all indices were reliable (split‐half r = 0.73–0.98). Caffeine affected neither commission errors (BF01 = 4.98), response criterion (5.14), Go reaction time (2.83), reaction time variability (4.35), flanker reaction time (5.49) nor flanker accuracy (5.09). ADHD symptoms moderated no effect (15 preregistered tests; smallest p = 0.514), yet predicted performance itself (flanker accuracy r = −0.42), indicating that the null is not due to an insensitive measure. Conclusions Caffeine produced no acute benefit for either form of inhibition, and ADHD symptoms did not moderate its effects. Bayes factors supported the absence rather than the nondetection of these effects, arguing against an acute improvement of inhibitory control that scales with ADHD symptom severity in nonclinical young adults. Whether this also holds for chronic consumption or for adults with diagnosed ADHD remains to be tested.
ABSTRACT Objective Recently, complement component 4A (C4A), a complement system protein, and neurofilament light chain (NfL), a neuroaxonal injury biomarker, have been found to be potentially implicated in the pathophysiology of psychosis. This study evaluated C4A and NfL levels before and after risperidone monotherapy in patients with psychosis. Methods This prospective observational study included 30 patients (18–45 years) with psychosis diagnosed according to DSM‐5 criteria and 30 healthy controls. Patients received risperidone monotherapy and were followed up for 8 weeks. Serum C4A and NfL levels were measured before and after 8 weeks of treatment in patients using enzyme‐linked immunosorbent assay (ELISA). In healthy controls, C4A and NfL levels were also measured once. Quality of life was assessed using the World Health Organization Quality of Life Brief Version (WHOQOL‐BREF) questionnaire. Results Serum NfL levels were significantly ( p < 0.001) higher, whereas serum C4A levels were not significantly higher in psychosis patients as compared to healthy controls. After 8 weeks of risperidone treatment, serum NfL levels did not change significantly, whereas serum C4A levels decreased significantly ( p < 0.001). WHOQOL‐BREF domain scores improved significantly (all p < 0.001) across all domains in psychosis patients. Conclusions The preliminary findings of the study suggest that risperidone monotherapy resulted in a significant reduction in serum C4A levels, whereas serum NfL levels did not change and remained elevated in patients with psychosis. In addition, risperidone monotherapy resulted in a significant improvement in quality of life. Serum C4A and NfL levels were measured using ELISA rather than ultrasensitive immunoassays. Therefore, larger longitudinal studies with longer follow‐up and ultrasensitive biomarker platforms are warranted to confirm these findings.